BlackRock
IMMX icon

BlackRock’s Immix Biopharma IMMX Stock Holding History

BlackRock’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.8M Buy
2,989,972
+2,521,595
+538% +$23.4M ﹤0.01% 2979
2026
Q1 		$4.27M Buy
468,377
+338,122
+260% +$2.48M ﹤0.01% 3891
2025
Q4 		$681K Buy
130,255
+87,187
+202% +$359K ﹤0.01% 4410
2025
Q3 		$90K Buy
43,068
+2,767
+7% +$6.64K ﹤0.01% 4852
2025
Q2 		$83.4K Buy
40,301
+28,477
+241% +$57.3K ﹤0.01% 4877
2025
Q1 		$19.9K Sell
11,824
-2,252
-16% -$4.25K ﹤0.01% 5093
2024
Q4 		$31K Buy
14,076
+73
+0.5% +$133 ﹤0.01% 5037
2024
Q3 		$20.9K Buy
14,003
+548
+4% +$1.1K ﹤0.01% 4931
2024
Q2 		$26.6K Sell
13,455
-5,866
-30% -$13.5K ﹤0.01% 4964
2024
Q1 		$59.3K Buy
19,321
+1,609
+9% +$6.23K ﹤0.01% 4837
2023
Q4 		$123K Sell
17,712
-279
-2% -$1.26K ﹤0.01% 4755
2023
Q3 		$61.5K Buy
17,991
+2,343
+15% +$5.49K ﹤0.01% 4967
2023
Q2 		$42.1K Buy
+15,648
New +$32.8K ﹤0.01% 5094
2022
Q2 		– Sell
-9,415
Closed -$22K – 5910
2022
Q1 		$22K Buy
+9,415
New +$35K ﹤0.01% 5556

Other funds holding IMMX

JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock's IMMX Position: Q2 2026 in Review

BlackRock increased its Immix Biopharma (IMMX) stake by 538% in Q2 2026, buying an estimated $23.4M and bringing the position to 2,989,972 shares worth $30.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2979.

BlackRock first reported a position in IMMX in Q1 2022 and has held it in 14 quarters since. 109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

  • BlackRock held 2,989,972 shares of Immix Biopharma worth $30.8M as of Q2 2026.
  • BlackRock bought 2,521,595 Immix Biopharma shares in Q2 2026, an estimated $23.4M.
  • Immix Biopharma made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2979 holding.
  • BlackRock first reported a position in Immix Biopharma in Q1 2022 and has held it in 14 quarters since.
  • 109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.